From polyaphron technology to fixed combinations, new formulations improve tolerability, adherence, and patient satisfaction.

Researchers conducted a phase 3b randomized study of a cohort in the VISIBLE trial, which included 103 adults with skin of color and moderate-to-severe psoriasis (mean age, 44.1 years; 28.2% women ...

Early intervention with IL-17 inhibitors among patients with plaque psoriasis is associated with improved relapse and remission rates.

These data indicate that "prolonged [TNF inhibitor] treatment plays a protective role in PsA development in severe psoriasis patients," the researchers wrote. This is important, in that some previous ...

Guselkumab and risankizumab for psoriasis have the highest rates of drug survival among biologics measured and a comparable safety profile.

The efficacy and safety of ESK-001 in adult patients with moderate-to-severe plaque psoriasis are currently being evaluated in the Phase 3 ONWARD clinical program, which consists of two parallel ...

This multicenter, randomized, double-blind, placebo-controlled trial randomized (1:1:1:1) 145 Chinese patients with moderate to severe plaque psoriasis to receive AC-201 25mg BID, 50mg BID or ...

Alumis Inc. completed patient enrollment in its Phase 3 trials for ESK-001, targeting moderate-to-severe plaque psoriasis. Quiver AI Summary. Alumis Inc. has announced the successful completion of ...

The efficacy and safety of ESK-001 in adult patients with moderate-to-severe plaque psoriasis are currently being evaluated in the Phase 3 ONWARD clinical program, which consists of two parallel ...